The Antimicrobial Resistance Diagnostics market is expected to grow at a CAGR of 6.9%, reaching USD 6.7 billion in 2031 from USD 4.8 billion in 2026.

The Antimicrobial Resistance (AMR) Diagnostics Market is growing as healthcare systems respond to the rising threat of drug-resistant infections. These diagnostics enable rapid identification of resistant pathogens, supporting targeted treatment decisions. Increasing global infection rates and demand for rapid testing solutions are driving adoption across hospitals and laboratories.

Description

Antimicrobial resistance diagnostics involve technologies used to detect pathogens and determine their resistance to antibiotics. Examples include molecular technologies, microbiological culture, immunological testing, and sequencing technologies. Diagnostic tests used in determining antimicrobial resistance will provide crucial information in determining the best selection of antimicrobials for the treatment of applicable patients and will help slow the spread of infection caused by resistant organisms. As the incidence of drug-resistant pathogens (e.g. MRSA) continues to rise globally, the demand for diagnostic products will continue to grow.

Growth Drivers

• Increasing Incidence of Hospital-Acquired Infections : The number of acquired infections in hospitals, which are caused by bacteria that are resistant to antibiotics, is on the rise across the globe. The increase in this type of infection is leading to a greater need for the creation of accurate diagnostic tests to identify and diagnose infections early in patients' lives and to assist with clinical management decisions when they get sick.

• Government and Global Health Initiatives : Governments and Global Health Organizations are investing in various programs to help to reduce the effects of antimicrobial resistance. The programs support the diffusion of new and advanced diagnostic testing technologies and assist in funding new testing methods.

• Technological Advancements in Diagnostics: Through ongoing development and advancements in diagnostic platforms, including molecular and automated testing, tests to provide rapid and accurate results regarding AMR are becoming more efficient at detecting resistance to antimicrobials. These improvements are providing incentives to healthcare providers to utilize advanced testing solutions.

• Growing Demand for Early and Accurate Diagnosis : When a resistant infection is detected early in patients, practitioners can provide appropriate treatments and decrease the chance of transmitting the course of the disease through proper infection control. AMR diagnostic tests enable more rapid detection of pathogens and resistance patterns. This helps healthcare providers deliver the appropriate treatment to patients sooner.

Challenges and Opportunities

• The National healthcare systems are facing many challenges, including high costs currently associated with advanced diagnostic testing technology, complex regulatory requirements for technology, and a lack of access for healthcare systems to diagnostic infrastructure in low-resource environments. However, with increased funding for rapid diagnostic testing, expanded point-of-care testing opportunities, and AI-driven analytics integrated into diagnostic testing, there is an increased opportunity for technology available from testing related to AMR. As antimicrobial resistance continues to grow globally, the future demand for fast, accurate, and accessible diagnostic solutions is expected to drive the overall market toward continued long-term growth.

Key Development

• June 2025: bioMérieux strengthened its antimicrobial resistance diagnostics capabilities by acquiring assets from Day Zero Diagnostics, a company specialising in genome sequencing and machine learning-based infectious disease detection. This acquisition enables faster identification of pathogens and their antibiotic resistance profiles directly from blood samples, significantly reducing diagnostic time from days to hours.

Market Segmentation

The market is segmented by product type, technology, application and geography.

By Product Type – Kits & Reagents

Kits and reagents are a vital segment within the antimicrobial resistance (AMR) diagnostics market, fulfilling an indispensable role in routine antimicrobial susceptibility testing (AST) performed in laboratories and hospitals. Kits and reagents consist of assay kits used to test for resistance, culture media used to grow bacteria, and molecular reagents used to identify the presence of resistant pathogens. Due to repetitive use of these products during the diagnostic workflow, they have a continual demand for use. With the growing need for rapid and accurate testing, manufacturers have created specialised kits to identify resistance genes and specific pathogens. These products support conventional and molecular diagnostic methodologies and are thus essential for the prompt identification of AMR and support the appropriate treatment of patients in hospital and clinical settings.

By Technology – Polymerase Chain Reaction (PCR)

The use of polymerase chain reaction (PCR) technology is very common in AMR diagnostics, as the ability to quickly and accurately amplify and identify the genetic material of pathogens and the associated resistance genes by PCR-based testing is viewed as a notable benefit. PCR-based testing provides both a high degree of sensitivity and specificity in detecting resistant infections, allowing for timely identification of education, and offering clinicians the means to make timely decisions when developing treatment plans for infected patients. The ability to reduce turnaround times compared to traditional culture methods provides hospitals and clinicians with the capacity to quickly implement effective antibiotics on their patients. Hospital laboratories commonly use PCR technology to identify drug-resistant bacteria and provide guidance in prescribing targeted antibiotic therapy. The continued development of real-time and multiplex PCR techniques continues to improve PCR technology's speed and efficiency while further expanding its capacity to support AMR diagnostics.

By Application – Clinical Diagnostics

The largest application segment in the AMR diagnostics market is clinical diagnostics, as most AMR tests are performed in hospitals and diagnostic laboratories to assist clinicians in selecting appropriate treatments for infected patients. Rapid identification of resistant pathogens allows clinicians to provide patients with effective antibiotics, thus reducing the number of failed treatments and preventing the further transmission of resistant infections. The rise in the number of hospital-acquired infections and the rise in the number of global incidents of resistance makes the use of antimicrobials critical for healthcare systems.

Regional Analysis

North America Market Analysis

The North American market is the largest market owing to an advanced healthcare system, many successful government programs, and high utilization of diagnostic technologies. The increase in drug-resistant infections and the presence of key companies will support the North American region with the largest revenue share.

South America Market Analysis

South America is gradually moving toward the adoption of more advanced diagnostic solutions as total health infrastructure continues to improve. The growing prevalence of infectious disease is expected to increase demand for AMR diagnostics in the South American region.

Europe Market Analysis

The growth trend in Europe will continue, driven by an increase in the general population's awareness of antimicrobial resistance and the establishment of strong regulatory frameworks. Government investments in public health surveillance systems and diagnostic infrastructures will help them to manage AMR effectively.

Middle East and Africa Market Analysis

Early-stage adoption of wearable biosensors within the Middle East and Africa (MEA) is motivated by improved healthcare accessibility and increasing interest in technical advancements for portable diagnostics.

Asia Pacific Market Analysis

Asia Pacific is experiencing rapid growth due to a high incidence of infectious disease, a large population base and increasing healthcare spending. Government and public awareness of AMR and government initiatives in Asia Pacific are supporting the adoption of AMR diagnostics.

List of Companies

·      Thermo Fisher Scientific

·      Roche Diagnostics

·      Bio-Rad Laboratories

·      QIAGEN

·      Danaher Corporation

·      Abbott Laboratories

·      bioMérieux

·      Bruker Corporation

·      Accelerate Diagnostics

·      Hologic

Abbott Laboratories

Abbott leads the market for wearable biosensors, particularly in the area of continuous glucose monitoring (CGM). Their FreeStyle Libre system has become the standard against which all others are compared, allowing patients with diabetes to monitor their blood sugar levels in real time without the hassle of repeatedly pricking their fingers. Abbott is working to combine biosensors with mobile platforms, so patients have an ongoing picture of their health status based on this continuous data. Abbott's highly developed global footprint, commitment to innovation and development of digital health ecosystems through partnerships have helped them cement their position as the leader in wearable diagnostics.

BioMérieux

BioMérieux is a top provider of diagnostic services for both infectious diseases and testing for resistance against antibiotics. Through its combined offerings of automated systems, test reagents and software, bioMérieux's products allow hospitals and/or laboratories to perform rapid identification of microorganisms as well as provide the test results necessary for initiating the most appropriate and effective treatment options for patients with an infectious disease. In addition, bioMérieux places a strong emphasis on developing innovative technologies and techniques to enhance the ability to accurately and quickly detect infections via microbiological as well as molecular diagnostic methods. bioMerieux's extensive global reach, coupled with its expertise in the discipline of infectious disease, uniquely position bioMérieux to assist in the drive to advance AMR diagnostic products and services and, subsequently, improve global healthcare delivery.

Antimicrobial Resistance Diagnostics Market Scope: